A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Investigator: Joseph Masdeu, MD

Study Coordinator: Mica-Gabrielle Mangibin

Status: Enrolling

ClinicalTrials.gov Number: NCT04437511

Phone: 713.441.3780

Protocol Number: PRO00025839


The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab.
More to Explore